Signatera is a custom-built circulating tumor DNA (ctDNA) test for molecular residual disease (MRD) assessment and treatment monitoring and in patients previously diagnosed with cancer. Signatera’s performance has been clinically validated in multiple solid tumors including colorectal, breast, and bladder cancers as well as for immunotherapy response monitoring.